Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?

Maria A Velez¹, Timothy F Burns^{2

3}

Affiliations

¹ Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
² Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
³ Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

Editorial

Maria A Velez et al. Transl Lung Cancer Res. 2019 Dec.

. 2019 Dec;8(Suppl 4):S339-S342.

doi: 10.21037/tlcr.2019.04.09.

Maria A Velez¹, Timothy F Burns^{2

3}

¹ Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
² Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
³ Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, Wolf B, Jones B, Madrigal J, Horton J, Spiegel M, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Lim C, Ma L, Adame C, Garon EB. Lisberg A, et al. J Thorac Oncol. 2018 Aug;13(8):1138-1145. doi: 10.1016/j.jtho.2018.03.035. Epub 2018 Jun 1. J Thorac Oncol. 2018. PMID: 29874546 Free PMC article. Clinical Trial.

1. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81. 10.1038/nrc2088 - DOI - PubMed
1. Kim HJ, Choi EY, Jin HJ, et al. Relationship between EGFR mutations and clinicopathological features of lung adenocarcinomas diagnosed via small biopsies. Anticancer Res 2014;34:3189-95. - PubMed
1. Liang H, Liu X, Wang M. Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. Onco Targets Ther 2018;11:6189-96. 10.2147/OTT.S178497 - DOI - PMC - PubMed
1. Zhang N, Zeng Y, Du W, et al. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Int J Oncol 2016;49:1360-8. 10.3892/ijo.2016.3632 - DOI - PubMed
1. Lisberg A, Cummings A, Goldman JW, et al. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. J Thorac Oncol 2018;13:1138-45. 10.1016/j.jtho.2018.03.035 - DOI - PMC - PubMed